Analysts Expect Theravance Biopharma Inc (TBPH) Will Post Quarterly Sales of $16.45 Million
Wall Street analysts expect that Theravance Biopharma Inc (NASDAQ:TBPH) will post sales of $16.45 million for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Theravance Biopharma’s earnings, with the highest sales estimate coming in at $19.44 million and the lowest estimate coming in at $13.90 million. Theravance Biopharma posted sales of $8.32 million during the same quarter last year, which indicates a positive year over year growth rate of 97.7%. The firm is expected to issue its next earnings report on Tuesday, May 14th.
According to Zacks, analysts expect that Theravance Biopharma will report full year sales of $67.86 million for the current year, with estimates ranging from $65.00 million to $69.70 million. For the next fiscal year, analysts anticipate that the company will post sales of $117.40 million, with estimates ranging from $105.00 million to $129.80 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Theravance Biopharma.
Several brokerages have commented on TBPH. BidaskClub raised Theravance Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 10th. Zacks Investment Research lowered shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a report on Thursday, January 10th. ValuEngine cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Tuesday, January 22nd. Finally, Cantor Fitzgerald assumed coverage on shares of Theravance Biopharma in a research note on Monday, January 28th. They issued a “buy” rating and a $55.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. Theravance Biopharma has a consensus rating of “Hold” and an average target price of $43.40.
In other news, SVP Sharathchandra S. Hegde sold 9,033 shares of the business’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $24.71, for a total transaction of $223,205.43. Following the sale, the senior vice president now directly owns 270,134 shares in the company, valued at $6,675,011.14. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 6.60% of the company’s stock.
A number of large investors have recently made changes to their positions in TBPH. Amundi Pioneer Asset Management Inc. raised its holdings in Theravance Biopharma by 34.1% during the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 5,500 shares of the biopharmaceutical company’s stock worth $141,000 after purchasing an additional 1,400 shares during the last quarter. FNY Investment Advisers LLC bought a new stake in shares of Theravance Biopharma in the 4th quarter valued at $42,000. Virtus ETF Advisers LLC lifted its position in shares of Theravance Biopharma by 7.2% during the 3rd quarter. Virtus ETF Advisers LLC now owns 32,226 shares of the biopharmaceutical company’s stock valued at $1,053,000 after acquiring an additional 2,171 shares during the period. Bank of New York Mellon Corp lifted its position in shares of Theravance Biopharma by 1.2% during the 4th quarter. Bank of New York Mellon Corp now owns 208,117 shares of the biopharmaceutical company’s stock valued at $5,326,000 after acquiring an additional 2,547 shares during the period. Finally, Quantamental Technologies LLC bought a new position in Theravance Biopharma during the fourth quarter worth $102,000. 84.94% of the stock is owned by institutional investors and hedge funds.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.
Read More: Asset Allocation and Your Retirement
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.